Skip to content

Frontiers in Psychiatry

ISSN 1664-0640

439 papers in the library · 7,744 citations · publishing 2011-2026

Papers

Sort Most recent Most cited

Co-design of Guidance for Patient and Public Involvement in Psychedelic Research

Frontiers in Psychiatry September 30, 2021 James B. Close, Julia Bornemann, Maria Piggin et al. 21 citations

Within the context of scientific research, patient and public involvement (PPI) is defined as research performed “with” or “by” patients and members of the public, rather than “to,” “about”, or “for” them. When carried out systematically and thoughtfully, PPI has the potential to strengthen the quality and impact of research by fostering accountability, transparency, and relevance. There exist...

MDMA-Assisted Therapy as a Means to Alter Affective, Cognitive, Behavioral, and Neurological Systems Underlying Social Dysfunction in Social Anxiety Disorder

Frontiers in Psychiatry September 27, 2021 Jason B. Luoma, M. Kati Lear 11 citations

Social anxiety disorder (SAD) is a prevalent and often debilitating psychiatric disorder that can assume a chronic course even when treated. Despite the identification of evidence-based pharmacological and behavioral treatments for SAD, much room for improved outcomes exists and 3,4-methylenedioxymethamphetamine (MDMA) has been proposed as a promising adjunctive treatment to psychological...

Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics

Frontiers in Psychiatry September 10, 2021 Cato M. H. de Vos, Natasha L. Mason, Kim P. C. Kuypers 259 citations

Clinical studies suggest the therapeutic potential of psychedelics, including ayahuasca, DMT, psilocybin, and LSD, in stress-related disorders. These substances induce cognitive, antidepressant, anxiolytic, and antiaddictive effects suggested to arise from biological changes similar to conventional antidepressants or the rapid-acting substance ketamine. The proposed route is by inducing brain...

New Frontiers or a Bursting Bubble? Psychedelic Therapy Beyond the Dichotomy

Frontiers in Psychiatry September 10, 2021 Tehseen Noorani, Jonny Martell 32 citations

The publication in April 2021 of the Imperial College London Phase II study investigating \nthe efficacy of psilocybin-assisted therapy vs. escitalopram for depression reported differences \nin the primary outcome measure (the QIDS-SR16) between experimental and control arms as \nstatistically insignificant (1). However, secondary measures of depression, and other relevant \nmeasures (see...

Mindfulness Training for Primary Care for Portuguese-Speaking Immigrants: A Pilot Study

Frontiers in Psychiatry September 9, 2021 Marcelo Trombka, Timothy B. Creedon, Marcelo Demarzo et al. 14 citations

Background: Portuguese-speaking immigrants are a growing underserved population in the Unites States who experience high levels of psychological distress and increased vulnerability to mental health disorders such as depression and anxiety. Current evidence shows that mindfulness-based interventions (MBIs) are effective to promote physical and mental health among educated English speakers;...

Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems

Frontiers in Psychiatry September 6, 2021 Elena Argento, Devon Christie, Lindsay Mackay et al. 12 citations

The COVID-19 pandemic stands to have impacts on mental health and well-being that will extend beyond its formal resolution. Before COVID-19, mental health disorders were already challenging global healthcare systems, directly accounting for 7.4% of the total burden of disease (1, 2). An estimated 1 billion people worldwide suffer from a mental health disorder, with the two most common...

Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy

Frontiers in Psychiatry August 11, 2021 Maria Eleni Eleftheriou, Emily M Thomas 37 citations

Mindfulness-based interventions and psychedelic-assisted therapy have been experimentally utilised in recent years as alternative treatments for various psychopathologies with moderate to great success. Both have also demonstrated significant post-acute and long-term decreases in clinical symptoms and enhancements in well-being in healthy participants. These two therapeutic interventions share...

Effects of Ayahuasca on Personality: Results of Two Randomized, Placebo-Controlled Trials in Healthy Volunteers

Frontiers in Psychiatry August 6, 2021 Juliana Mendes Rocha, Giordano Novak Rossi, Flávia de Lima Osório et al. 37 citations

Rationale: Previous studies with the serotonergic hallucinogens LSD and psilocybin showed that these drugs induced changes in personality traits, such as increases in Openness. However, results are inconsistent, and the effects of ayahuasca on personality were never investigated in a controlled trial. Objectives: To assess the effects of ayahuasca on personality in two randomized,...

Moral Psychopharmacology Needs Moral Inquiry: The Case of Psychedelics

Frontiers in Psychiatry August 2, 2021 Nicolas Langlitz, Erika Dyck, Milan Scheidegger et al. 35 citations

The revival of psychedelic research coincided and more recently conjoined with psychopharmacological research on how drugs affect moral judgments and behaviors. This article makes the case for a moral psychopharmacology of psychedelics that examines whether psychedelics serve as non-specific amplifiers that enable subjects to (re-)connect with their values, or whether they promote specific...

Effects of Mindfulness-Based Cognitive Therapy on Stigma in Female Patients With Schizophrenia

Frontiers in Psychiatry July 23, 2021 Qiubi Tang, Shuixian Yang, Cuixian Liu et al.

Mindfulness-based cognitive therapy (MBCT) has been increasingly recognized as effective in different mental illnesses, but these effects are limited in schizophrenia. For patients with schizophrenia, stigma is one of the most negative factors that affects treatment, rehabilitation and social function. This research aimed to determine the effects of MBCT on stigma in patients with...

Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?

Frontiers in Psychiatry July 19, 2021 Rita Kočárová, Jiřı́ Horáček, Robin Carhart-Harris 95 citations

Addressing global mental health is a major 21st-century challenge. Current treatments have recognized limitations; in this context, new ones that are prophylactic and effective across diagnostic boundaries would represent a major advance. The view that there exists a core of transdiagnostic overlap between psychiatric disorders has re-emerged in recent years, and evidence that psychedelic...

The Ethic of Access: An AIDS Activist Won Public Access to Experimental Therapies, and This Must Now Extend to Psychedelics for Mental Illness

Frontiers in Psychiatry July 5, 2021 Morgan Campbell, Monnica T. Williams

If patients with mental illnesses are to be treated fairly in comparison with other categories of patients, they must be given access to promising experimental therapies, including psychedelics. The right of early access to promising therapies was advanced as an ethical principle by activist Larry Kramer during the AIDS pandemic, and has now largely been adopted by the medical establishment....

Sustained, Multifaceted Improvements in Mental Well-Being Following Psychedelic Experiences in a Prospective Opportunity Sample

Frontiers in Psychiatry June 29, 2021 Keri Mans, Hannes Kettner, David Erritzøe et al. 65 citations

In the last 15 years, psychedelic substances, such as LSD and psilocybin, have regained legitimacy in clinical research. In the general population as well as across various psychiatric populations, mental well-being has been found to significantly improve after a psychedelic experience. Mental well-being has large socioeconomic relevance, but it is a complex, multifaceted construct. In this...

Yoga of Immortals Intervention Reduces Symptoms of Depression, Insomnia and Anxiety

Frontiers in Psychiatry June 22, 2021 Sadhna Verma, James Donovan, Hari S. Tunuguntla et al.

Background: Depression, anxiety, and disordered sleep are some common symptoms associated with sub-optimal mental health. During the COVID-19 pandemic, mental health issues have grown increasingly more prevalent in the population. Due to social distancing and other limitations during the pandemic, there is a need for home-based, flexible interventions that can improve mental health. The Yoga of...

Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study

Frontiers in Psychiatry June 16, 2021 Dóra Révész, Genís Ona, Giordano Novak Rossi et al. 42 citations

Background: One of the main public health strategies adopted at the beginning of the COVID-19 pandemic consisted of implementing strict lockdowns to stop the transmission of the virus. Despite being an effective measure, the confinement and the associated social isolation create a stressful, potentially lengthy situations that has been proven to have several psychological consequences. Given...

Ceremonial Ayahuasca in Amazonian Retreats—Mental Health and Epigenetic Outcomes From a Six-Month Naturalistic Study

Frontiers in Psychiatry June 9, 2021 Simon Ruffell, Nige Netzband, WaiFung Tsang et al. 74 citations

Ayahuasca is a natural psychoactive brew, used in traditional ceremonies in the Amazon basin. Recent research has indicated that ayahuasca is pharmacologically safe and its use may be positively associated with improvements in psychiatric symptoms. The mechanistic effects of ayahuasca are yet to be fully established. In this prospective naturalistic study, 63 self-selected participants took...

Subcutaneous Ketamine in Depression: A Systematic Review

Frontiers in Psychiatry May 28, 2021 V. B. Cavenaghi, Leandro Paulino da Costa, Acioly L T Lacerda et al. 41 citations

Background: Ketamine has been shown to produce a rapid and robust antidepressant effect. Though numerous routes of administration have been studied, subcutaneous (SC) has proven to be a convenient and cost-effective route making its use particularly relevant in developing countries. Here we provide a systematic review covering the use of SC racemic ketamine and esketamine in depression,...

The Effects of Mindfulness-Based Stress Reduction on Negative Self-Representations in Social Anxiety Disorder—A Randomized Wait-List Controlled Trial

Frontiers in Psychiatry May 12, 2021 Liguo He, Wei Han, Zhan Shi

This study examines the impact of mindfulness-based stress reduction (MBSR) vs. wait list (WL) on the self-reference effect involving negative adjectives in individuals with social anxiety disorder (SAD). Eighty-five participants with SAD were randomly assigned to 12 weeks of MBSR or WL and completed an incidental SRE task that assessed treatment-related negative self-representations....

Repeated Dosing of Ketamine in the Forced Swim Test: Are Multiple Shots Better Than One?

Frontiers in Psychiatry May 11, 2021 Ridge G. Weston, Paul J. Fitzgerald, Brendon O. Watson 19 citations

The anesthetic drug ketamine has been successfully repurposed as an antidepressant in human subjects. This represents a breakthrough for clinical psychopharmacology, because unlike monoaminergic antidepressants, ketamine has rapid onset, including in Major Depressive Disorder (MDD) that is resistant to conventional pharmacotherapy. This rapid therapeutic onset suggests a unique mechanism of...

Psilocybin: From Serendipity to Credibility?

Frontiers in Psychiatry April 21, 2021 James Rucker, Allan H. Young 40 citations

Psilocybin has a long history of non-medical use and some seem to infer from this that it has therapeutic utility. Early phase clinical trials with psilocybin are encouraging, but suggest only that larger, multicentre trials are required. These are ongoing but will take many years to complete. Meanwhile, retreat centers offering paid experiences with psilocybin truffles have opened in some...

Psychotherapy in the Framework of Embodied Cognition—Does Interpersonal Synchrony Influence Therapy Success?

Frontiers in Psychiatry March 22, 2021 M. A. Mende, Hendrik Schmidt

Mental health problems remain among the main generators of costs within and beyond the health care system. Psychotherapy, the tool of choice in their treatment, is qualified by social interaction, and cooperation within the therapist-patient-dyad. Research into the factors influencing therapy success to date is neither exhaustive nor conclusive. Among many others, the quality of the...

Mindfulness Training Improves Quality of Life and Reduces Depression and Anxiety Symptoms Among Police Officers: Results From the POLICE Study—A Multicenter Randomized Controlled Trial

Frontiers in Psychiatry February 26, 2021 Marcelo Trombka, Marcelo Demarzo, Daniel Fernando Campos et al.

Background: Police officers' high-stress levels and its deleterious consequences are raising awareness to an epidemic of mental health problems and quality of life (QoL) impairment. There is a growing evidence that mindfulness-based interventions are efficacious to promote mental health and well-being among high-stress occupations. Methods: The POLICE study is a multicenter randomized...

Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach

Frontiers in Psychiatry February 9, 2021 Valeria Catalani, Davide Arillotta, John Corkery et al. 38 citations

COVID-19-related disruptions of people and goods' circulation can affect drug markets, especially for new psychoactive substances (NPSs). Drug shortages could cause a change in available NPS, with the introduction of new, unknown, substances. The aims of the current research were to use a web crawler, NPSfinder®, to identify and categorize emerging NPS discussed on a range of drug...

Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research

Frontiers in Psychiatry February 3, 2021 Sara Tai, Elizabeth M. Nielson, Molly Lennard-Jones et al. 87 citations

Introduction: Psychological support throughout psilocybin therapy is mandated by regulators as an essential part of ensuring participants' physical and psychological safety. There is an increased need for specially trained therapists who can provide high-quality care to participants in clinical studies. This paper describes the development and practical implementation of a therapist training...

The Antidepressant-Like Effects of a Clinically Relevant Dose of Ketamine Are Accompanied by Biphasic Alterations in Working Memory in the Wistar Kyoto Rat Model of Depression

Frontiers in Psychiatry January 20, 2021 Conor McDonnell, F. Dunphy-Doherty, J. Rouine et al.

Major depressive disorder (MDD) is the leading cause of disability worldwide. The majority of antidepressant drugs require several weeks or months of treatment to demonstrate efficacy and a subset of patients are resistant to such interventions. Ketamine demonstrates rapid and long-lasting antidepressant effects in treatment resistant patients; however, side effects may limit its widespread...